Elisabet Nielsen
Senior Lecturer/Associate Professor at Institutionen för farmaci; Farmakometri
- Telephone:
- +46 18 471 42 27
- E-mail:
- elisabet.nielsen@farmaci.uu.se
- Visiting address:
- Biomedicinskt Centrum BMC, Husargatan 3
752 37 Uppsala - Postal address:
- Box 580
751 23 UPPSALA
Download contact information for Elisabet Nielsen at Institutionen för farmaci; Farmakometri
Senior Lecturer/Associate Professor at Institutionen för farmaci; Klinisk farmaci och farmakoterapi
- Visiting address:
- Biomedicinskt Centrum BMC, Husargatan 3
752 37 Uppsala - Postal address:
- Box 580
751 23 UPPSALA
More information is available to staff who log in.
Short presentation
Elisabet Nielsen is an Associate Professor and Senior Lecturer in Clinical Pharmacy at the Department of Pharmacy, Uppsala University, Sweden. Elisabet graduated in 1998 with a MSc in Pharmaceutical Sciences, and in 2011 she received her PhD. Her research focus on developing, implementing and evaluating methods for individualized drug treatments in various therapeutic areas and patient populations.
Keywords
- bacterial infections
- clinical pharmacy
- clinical research
- clinical trials
- copd
- dose individualization
- drug treatment optimization
- therapeutic drug monitoring
Publications
Selection of publications
- Population Pharmacokinetics of Plasma-Derived Factor IX (2016)
- Simulation-Based Evaluation of PK/PD Indices for Meropenem Across Patient Groups and Experimental Designs (2016)
- PK/PD Index Versus Mechanism-Based PKPD Modeling to Describe Antibacterial Efficacy of Ciprofloxacin and Colistin (2013)
- Pharmacokinetic-Pharmacodynamic Modeling of Antibacterial Drugs (2013)
- Pharmacometric Models for Antibacterial Agents to Improve Dosing Strategies (2011)
- Pharmacokinetic/Pharmacodynamic (PK/PD) indices of antibiotics predicted by a semi-mechanistic PKPD model (2011)
- Developmental Pharmacokinetics of Gentamicin in Preterm and Term Neonates (2009)
- Semimechanistic pharmacokinetic/pharmacodynamic model for assessment of activity of antibacterial agents from time-kill curve experiments (2007)
Recent publications
- Failure to Involve Older Hospitalised Patients in Medication Decisions (2024)
- Predicting cytokine kinetics during sepsis; a modelling framework from a porcine sepsis model with live Escherichia coli (2023)
- The complexities of communication at hospital discharge of older patients (2023)
- Risk factors for and preventability of drug‐related hospital revisits in older patients (2023)
- Synergy of polymyxin B and minocycline against KPC-3- and OXA-48-producing Klebsiella pneumoniae in dynamic time-kill experiments (2023)
All publications
Articles
- Failure to Involve Older Hospitalised Patients in Medication Decisions (2024)
- Predicting cytokine kinetics during sepsis; a modelling framework from a porcine sepsis model with live Escherichia coli (2023)
- The complexities of communication at hospital discharge of older patients (2023)
- Risk factors for and preventability of drug‐related hospital revisits in older patients (2023)
- Synergy of polymyxin B and minocycline against KPC-3- and OXA-48-producing Klebsiella pneumoniae in dynamic time-kill experiments (2023)
- Therapeutic drug monitoring of vancomycin and meropenem (2023)
- Model‐based assessment of neutrophil‐mediated phagocytosis and digestion of bacteria across in vitro and in vivo studies (2023)
- Imitation of β-lactam binding enables broad-spectrum metallo-β-lactamase inhibitors (2022)
- Research priorities towards precision antibiotic therapy to improve patient care (2022)
- Changes in critical inhaler technique errors in inhaled COPD treatment (2022)
- Population pharmacokinetics of cefotaxime in intensive care patients (2022)
- Quantitation of seven sedative and analgesic drugs in whole blood from intensive care patients using liquid chromatography mass spectrometry (2021)
- Effects of Hospital-Based Comprehensive Medication Reviews Including Postdischarge Follow-up on Older Patients' Use of Health Care (2021)
- Continuous infusion of piperacillin‐tazobactam significantly improves target attainment in children with cancer and fever (2021)
- Critical inhaler technique errors in Swedish patients with COPD (2021)
- From Therapeutic Drug Monitoring to Model-Informed Precision Dosing for Antibiotic (2021)
- Relationship between factor VIII activity, bleeds and individual characteristics in severe hemophilia A patients (2020)
- Intervention fidelity and process outcomes of medication reviews including post-discharge follow-up in older hospitalized patients (2020)
- A novel mechanism-based pharmacokinetic-pharmacodynamic (PKPD) model describing ceftazidime/avibactam efficacy against β-lactamase-producing Gram-negative bacteria (2020)
- Efficacy of Antibiotic Combinations against Multidrug-Resistant Pseudomonas aeruginosa in Automated Time-Lapse Microscopy and Static Time-Kill Experiments (2020)
- Population pharmacokinetics of levodopa gel infusion in Parkinson's disease (2020)
- Pharmacodynamics of immune response biomarkers of interest for evaluation of treatment effects in bacterial infections (2020)
- Extension of Pharmacokinetic/Pharmacodynamic Time-Kill Studies To Include Lipopolysaccharide/Endotoxin Release from Escherichia coli Exposed to Cefuroxime. (2020)
- Evaluation of polymyxin B in combination with 13 other antibiotics against carbapenemase-producing Klebsiella pneumoniae in time-lapse microscopy and time-kill experiments (2020)
- Combination of polymyxin B and minocycline against multidrug-resistant Klebsiella pneumoniae (2020)
- Handling interoccasion variability in model-based dose individualization using therapeutic drug monitoring data (2019)
- Bayesian Forecasting Utilizing Bleeding Information to Support Dose Individualization of Factor VIII (2019)
- Pharmacokinetics of Caspofungin in Critically Ill Patients in Relation to Liver Dysfunction (2019)
- Piperacillin pharmacokinetics and target attainment in children with cancer and fever (2019)
- A Cross-Sectional Study Assessing Appropriateness Of Inhaled Corticosteroid Treatment In Primary And Secondary Care Patients With COPD In Sweden (2019)
- A non-linear mixed effect model for innate immune response (2019)
- Population pharmacokinetics of piperacillin in febrile children receiving cancer chemotherapy (2019)
- Semi-mechanistic pharmacokinetic-pharmacodynamic modelling of antibiotic drug combinations (2018)
- Predicting mutant selection in competition experiments with ciprofloxacin-exposed Escherichia coli (2018)
- Real life experiences of a PK dosing study (2018)
- The risk of febrile neutropenia in breast cancer patients following adjuvant chemotherapy is predicted by the time course of interleukin-6 and C-reactive protein by modelling. (2018)
- Population pharmacokinetics of levodopa/carbidopa microtablets in healthy subjects and Parkinson’s disease patients (2018)
- Automated time-lapse microscopy a novel method for screening of antibiotic combination effects against multidrug-resistant Gram-negative bacteria (2018)
- Elucidation of Factor VIII Activity Pharmacokinetics (2017)
- A non-fatal intoxication and seven deaths involving the dissociative drug 3-MeO-PCP (2017)
- Medication Reviews Bridging Healthcare (MedBridge) (2017)
- Elimination ability of caspofungin in critically ill patients in relation to liver dysfunction in an ICU setting (2017)
- Model-based prediction of myelosuppression and recovery based on frequent neutrophil monitoring (2017)
- Population Pharmacokinetic Analysis of Vaginally and Intravenously Administered Oxytocin in Postmenopausal Women (2017)
- Can a pharmacokinetic/pharmacodynamic (PKPD) model be predictive across bacterial densities and strains? (2017)
- A whole-body physiologically based pharmacokinetic (WB-PBPK) model of ciprofloxacin (2017)
- Levodopa-entacapone-carbidopa intestinal gel in Parkinson's disease (2017)
- Population Pharmacokinetic Modeling as a Tool To Characterize the Decrease in Ciprofloxacin Free Interstitial Levels Caused by Pseudomonas aeruginosa Biofilm Lung Infection in Wistar Rats (2017)
- The role of infection models and PK/PD modelling for optimising care of critically ill patients with severe infections (2017)
- Evaluation of automated time-lapse microscopy for assessment of in vitro activity of antibiotics (2017)
- Population Pharmacokinetics of Plasma-Derived Factor IX (2016)
- Development and Evaluation of a Gentamicin Pharmacokinetic Model That Facilitates Opportunistic Gentamicin Therapeutic Drug Monitoring in Neonates and Infants (2016)
- A pharmacokinetic-pharmacodynamic (PKPD) model based on in vitro time-kill data predicts the in vivo PK/PD index of colistin (2016)
- Simulation-Based Evaluation of PK/PD Indices for Meropenem Across Patient Groups and Experimental Designs (2016)
- Dynamic interaction of colistin and meropenem on a WT and a resistant strain of Pseudomonas aeruginosa as quantified in a PK/PD model (2016)
- A pharmacokinetic-pharmacodynamic model characterizing the emergence of resistant Escherichia coli subpopulations during ertapenem exposure (2016)
- A mechanism-based pharmacokinetic/pharmacodynamic model allows prediction of antibiotic killing from MIC values for WT and mutants (2015)
- A Neonatal Amikacin Covariate Model Can Be Used to Predict Ontogeny of Other Drugs Eliminated Through Glomerular Filtration in Neonates (2014)
- Population pharmacokinetics of plasma-derived factor IX (2014)
- Population pharmacokinetics of daptomycin in patients affected by severe Gram-positive infections (2013)
- PK/PD Index Versus Mechanism-Based PKPD Modeling to Describe Antibacterial Efficacy of Ciprofloxacin and Colistin (2013)
- Pharmacokinetic-Pharmacodynamic Modeling of Antibacterial Drugs (2013)
- Pharmacokinetic-pharmacodynamic model for gentamicin and its adaptive resistance with predictions of dosing schedules in newborn infants (2012)
- Predicting in vitro antibacterial efficacy across experimental designs with a semimechanistic pharmacokinetic-pharmacodynamic model (2011)
- Pharmacokinetic/Pharmacodynamic (PK/PD) indices of antibiotics predicted by a semi-mechanistic PKPD model (2011)
- Developmental Pharmacokinetics of Gentamicin in Preterm and Term Neonates (2009)
- Semimechanistic pharmacokinetic/pharmacodynamic model for assessment of activity of antibacterial agents from time-kill curve experiments (2007)
- Direct analysis of artemisinin in plasma and saliva using coupled-column high-performance liquid chromatography with a restricted-access material pre-column (2000)
- Relationship between factor VIII activity, bleeds and individual characteristics in severe hemophilia A patients
- Simulation-based evaluation of PK/PD indices for meropenem across patient groups and experimental designs
- Synergy of polymyxin B and minocycline against KPC-3- and OXA-48-producing Klebsiella pneumoniae in dynamic time-kill experiments: high agreement with in silico predictions
- Model-based assessment of neutrophil-mediated phagocytosis and digeston of bacteria across in vitro and in vivo studies
- Endotoxin challenge models: Model-based translation from piglets to healthy volunteers
- Physiological response to endotoxin: Linking hemodynamic and respiratory longitudinal changes through modelling
- A framework to assess antibiotic effects using time-lapse microscopy
- Quantifying combined effects of colistin and ciprofloxacin against Escherichia coli in an in silico pharmacokinetic-pharmacodynamic model
- Translational PKPD modelling and simulation framework to explore the combined effect of polymyxin B and minocycline against Klebsiella pneumoniae
Books
